In Pursuit of Targeted Therapies

Andrew Stainthorpe, PhD

Video Categories: Targeted Therapies

As we learn more about a person’s genetic makeup, the more we are able to target medicines to his/her needs and benefit. With continued research, Dr. Stainthorpe explains, we will be able to identify markers that allow us to target medicines more precisely to get better performance and reduce waste.
November 10, 2012

PMO Interview with the Innovator Series: Volume 1

Deborah Dunsire, MD, President and CEO of Millennium: The Takeda Oncology Company, and Kathy Giusti, Founder and CEO of the Multiple Myeloma Research Foundation, discuss the issues and vision in improving personalized medicine strategies for patients with multiple myeloma.Deborah Dunsire, MD, is the former President and CEO of Millennium Pharmaceuticals, [ Read More ]

July 13, 2021

Real-World Management of Thyroid Cancer with TRK Inhibitors

Dr Ezra Cohen of UC San Diego, La Jolla, CA, and Dr Mary Fidler of Rush University Medical Center, Chicago, IL, recount their clinical experiences and the journeys of patients treated with TRK inhibitors for thyroid cancer.